Is Avalglucosidase Alfa safe while breastfeeding?
Here is what NIH LactMed, the U.S. National Library of Medicine's authority on medicines and breastfeeding, reports about Avalglucosidase Alfa. This is a summary of that source — not our own verdict.
Effects on the breastfed infant
A woman with late-onset Pompe disease was treated with alglucosidase starting after delivery. The infant was breastfed, with the instruction not to breastfeed for 24 hours after each infusion. At 2 months postpartum, therapy was changed to avalglucosidase. At 8 months postpartum, the infant was developing normally.[ 2 ] A woman with late-onset Pompe disease was treated with avalglucosidase 20 mg/kg every 2 weeks during pregnancy and postpartum. Her infant was exclusively breastfed for 6 months and partially thereafter. The child was developing normally at follow-up at the age of 9 months.[ 1 ]
Effects on milk supply
Relevant published information was not found as of the revision date.
Levels in milk
Maternal Levels. Relevant published information was not found as of the revision date. Infant Levels. Acid alphaglucosidase activity was measured in 6 dried blood spots from an infant whose mother was receiving avalglucosidase alfa 20 mg/kg every 2 weeks. Samples taken at various times after the maternal infusion had values ranging from about 1 to 9 micromol/L/hour of acid alphaglucosidase activity. In comparison, the mother s blood acid alphaglucosidase activities before a dose were 0.5 micromol/L/hour and 169 micromol/L/hour 4 hours after a dose.[ 1 ]
Alternatives LactMed lists
Source: NIH LactMed (National Library of Medicine).
Educational summary of an authoritative source — not medical advice. Never start, stop, or change a medicine while breastfeeding without confirming with your doctor.